| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myasthenia Gravis | 24 | 2023 | 32 | 5.160 |
Why?
|
| T-Lymphocytes, Regulatory | 7 | 2014 | 30 | 2.230 |
Why?
|
| Myasthenia Gravis, Autoimmune, Experimental | 7 | 2014 | 7 | 1.980 |
Why?
|
| Receptors, Cholinergic | 12 | 2014 | 24 | 1.890 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 6 | 2012 | 19 | 1.460 |
Why?
|
| Autoantibodies | 8 | 2018 | 62 | 1.250 |
Why?
|
| Muscle, Skeletal | 9 | 2014 | 323 | 1.190 |
Why?
|
| Immunotherapy | 4 | 2017 | 50 | 1.080 |
Why?
|
| Mycophenolic Acid | 5 | 2006 | 12 | 1.040 |
Why?
|
| Muscle Weakness | 5 | 2014 | 27 | 0.810 |
Why?
|
| Immunosuppressive Agents | 7 | 2009 | 113 | 0.730 |
Why?
|
| Humans | 56 | 2023 | 23169 | 0.670 |
Why?
|
| Amyotrophic Lateral Sclerosis | 2 | 2016 | 22 | 0.670 |
Why?
|
| Autoimmune Diseases | 3 | 2015 | 26 | 0.630 |
Why?
|
| Muscular Diseases | 2 | 2018 | 12 | 0.620 |
Why?
|
| Electrodiagnosis | 3 | 2005 | 6 | 0.560 |
Why?
|
| Muscular Atrophy, Spinal | 4 | 2003 | 5 | 0.560 |
Why?
|
| Neuromuscular Junction Diseases | 3 | 2015 | 3 | 0.560 |
Why?
|
| Muscle Fibers, Skeletal | 3 | 2015 | 39 | 0.560 |
Why?
|
| Treatment Outcome | 9 | 2023 | 2971 | 0.550 |
Why?
|
| Forkhead Transcription Factors | 4 | 2012 | 16 | 0.550 |
Why?
|
| B-Lymphocytes | 2 | 2016 | 50 | 0.540 |
Why?
|
| Electromyography | 6 | 2005 | 68 | 0.530 |
Why?
|
| Cell Proliferation | 4 | 2014 | 165 | 0.520 |
Why?
|
| TDP-43 Proteinopathies | 1 | 2016 | 83 | 0.450 |
Why?
|
| Female | 29 | 2021 | 13059 | 0.450 |
Why?
|
| Antibody Specificity | 2 | 2011 | 19 | 0.440 |
Why?
|
| Receptors, Nicotinic | 2 | 2012 | 5 | 0.440 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2014 | 2 | 0.430 |
Why?
|
| Immunoglobulins, Intravenous | 3 | 2014 | 15 | 0.420 |
Why?
|
| Mice | 9 | 2014 | 1232 | 0.420 |
Why?
|
| Animals | 11 | 2014 | 3272 | 0.410 |
Why?
|
| Muscular Atrophy | 2 | 2018 | 11 | 0.410 |
Why?
|
| Male | 29 | 2021 | 12556 | 0.400 |
Why?
|
| Mice, Inbred C57BL | 6 | 2014 | 357 | 0.390 |
Why?
|
| Autoimmunity | 2 | 2010 | 12 | 0.360 |
Why?
|
| Adult | 22 | 2018 | 7031 | 0.340 |
Why?
|
| Middle Aged | 21 | 2018 | 8000 | 0.310 |
Why?
|
| Death Domain Receptor Signaling Adaptor Proteins | 1 | 2008 | 1 | 0.300 |
Why?
|
| Dendritic Cells | 4 | 2011 | 34 | 0.290 |
Why?
|
| Caspase 8 | 1 | 2008 | 10 | 0.290 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2008 | 7 | 0.290 |
Why?
|
| Neuroblastoma | 1 | 2008 | 17 | 0.290 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 230 | 0.280 |
Why?
|
| Apoptosis | 1 | 2008 | 196 | 0.270 |
Why?
|
| Immune Tolerance | 3 | 2012 | 12 | 0.260 |
Why?
|
| Neck Muscles | 1 | 2006 | 6 | 0.260 |
Why?
|
| Head Movements | 1 | 2006 | 6 | 0.260 |
Why?
|
| Antibodies | 4 | 2009 | 44 | 0.260 |
Why?
|
| Hodgkin Disease | 1 | 2006 | 19 | 0.260 |
Why?
|
| Radiotherapy | 1 | 2006 | 32 | 0.260 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2005 | 88 | 0.250 |
Why?
|
| Dermatomyositis | 1 | 2006 | 9 | 0.250 |
Why?
|
| Aged | 12 | 2018 | 7498 | 0.240 |
Why?
|
| Immunoassay | 1 | 2005 | 35 | 0.240 |
Why?
|
| Immunoglobulin G | 4 | 2014 | 69 | 0.230 |
Why?
|
| Nervous System Diseases | 1 | 2005 | 99 | 0.220 |
Why?
|
| Neural Conduction | 3 | 2001 | 11 | 0.200 |
Why?
|
| Interleukin-10 | 2 | 2014 | 18 | 0.200 |
Why?
|
| Muscle Fatigue | 1 | 2003 | 8 | 0.200 |
Why?
|
| Lymphocyte Activation | 2 | 2014 | 76 | 0.200 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 2 | 2012 | 11 | 0.200 |
Why?
|
| CD4 Antigens | 2 | 2012 | 29 | 0.190 |
Why?
|
| Polyradiculoneuropathy | 1 | 2002 | 2 | 0.190 |
Why?
|
| Polymyositis | 1 | 2002 | 7 | 0.190 |
Why?
|
| Immunity, Humoral | 2 | 2014 | 6 | 0.190 |
Why?
|
| Gastrostomy | 1 | 2001 | 9 | 0.180 |
Why?
|
| Positive-Pressure Respiration | 1 | 2001 | 11 | 0.180 |
Why?
|
| Activities of Daily Living | 1 | 2023 | 355 | 0.180 |
Why?
|
| Spinal Muscular Atrophies of Childhood | 1 | 2021 | 3 | 0.180 |
Why?
|
| Cholinesterase Inhibitors | 3 | 2009 | 12 | 0.180 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2021 | 29 | 0.180 |
Why?
|
| Double-Blind Method | 4 | 2023 | 382 | 0.180 |
Why?
|
| Muscular Dystrophy, Emery-Dreifuss | 2 | 2011 | 2 | 0.180 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2018 | 55 | 0.170 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2010 | 78 | 0.170 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2012 | 6 | 0.170 |
Why?
|
| Biological Products | 1 | 2021 | 31 | 0.170 |
Why?
|
| Neuromuscular Diseases | 1 | 2000 | 5 | 0.170 |
Why?
|
| Axons | 1 | 2000 | 24 | 0.170 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2000 | 1 | 0.160 |
Why?
|
| Torpedo | 2 | 2010 | 2 | 0.160 |
Why?
|
| Interferon-alpha | 1 | 2000 | 30 | 0.160 |
Why?
|
| Membrane Proteins | 3 | 2011 | 151 | 0.160 |
Why?
|
| X Chromosome | 1 | 1999 | 8 | 0.160 |
Why?
|
| Genetic Linkage | 1 | 1999 | 30 | 0.160 |
Why?
|
| Demyelinating Diseases | 1 | 1999 | 12 | 0.150 |
Why?
|
| Motor Neurons | 1 | 1999 | 15 | 0.150 |
Why?
|
| Muscular Dystrophies, Limb-Girdle | 1 | 2018 | 1 | 0.150 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2018 | 2 | 0.150 |
Why?
|
| Bulbo-Spinal Atrophy, X-Linked | 1 | 2018 | 1 | 0.150 |
Why?
|
| Neuromuscular Junction | 3 | 2009 | 7 | 0.150 |
Why?
|
| Nerve Block | 1 | 1999 | 61 | 0.140 |
Why?
|
| Connective Tissue Diseases | 1 | 1997 | 5 | 0.140 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1997 | 26 | 0.140 |
Why?
|
| Case-Control Studies | 2 | 2012 | 481 | 0.130 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 15 | 0.130 |
Why?
|
| Severity of Illness Index | 4 | 2009 | 811 | 0.130 |
Why?
|
| Reproduction | 1 | 2016 | 9 | 0.130 |
Why?
|
| Age of Onset | 3 | 2009 | 73 | 0.130 |
Why?
|
| Complement Inactivating Agents | 1 | 2016 | 2 | 0.120 |
Why?
|
| Orphan Drug Production | 1 | 2015 | 1 | 0.120 |
Why?
|
| Plasma Cells | 1 | 2016 | 5 | 0.120 |
Why?
|
| 4-Aminopyridine | 1 | 2015 | 3 | 0.120 |
Why?
|
| Potassium Channel Blockers | 1 | 2015 | 5 | 0.120 |
Why?
|
| Prednisone | 3 | 2006 | 64 | 0.120 |
Why?
|
| Thymectomy | 2 | 2009 | 2 | 0.120 |
Why?
|
| Child | 4 | 2021 | 1171 | 0.120 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 94 | 0.120 |
Why?
|
| Renal Dialysis | 3 | 2004 | 82 | 0.120 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2005 | 27 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2009 | 100 | 0.110 |
Why?
|
| DNA Mutational Analysis | 2 | 2011 | 50 | 0.110 |
Why?
|
| Physicians | 1 | 2015 | 106 | 0.110 |
Why?
|
| Chronic Disease | 3 | 2008 | 389 | 0.110 |
Why?
|
| Neurologic Examination | 2 | 2004 | 84 | 0.100 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 172 | 0.100 |
Why?
|
| Cytokines | 2 | 2012 | 206 | 0.100 |
Why?
|
| Drug Therapy, Combination | 2 | 2006 | 161 | 0.100 |
Why?
|
| Sensitivity and Specificity | 2 | 2005 | 449 | 0.100 |
Why?
|
| Self Tolerance | 1 | 2012 | 1 | 0.100 |
Why?
|
| Mutation | 2 | 2011 | 328 | 0.100 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2012 | 4 | 0.100 |
Why?
|
| Antigen-Presenting Cells | 1 | 2012 | 8 | 0.100 |
Why?
|
| Cell Separation | 1 | 2012 | 21 | 0.100 |
Why?
|
| Cells, Cultured | 1 | 2014 | 472 | 0.100 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2012 | 37 | 0.100 |
Why?
|
| Autoantigens | 1 | 2012 | 15 | 0.100 |
Why?
|
| In Vitro Techniques | 1 | 2012 | 152 | 0.100 |
Why?
|
| Cholinergic Antagonists | 1 | 2011 | 6 | 0.090 |
Why?
|
| Adoptive Transfer | 1 | 2011 | 31 | 0.090 |
Why?
|
| Stem Cells | 1 | 2011 | 34 | 0.090 |
Why?
|
| Exons | 1 | 2011 | 30 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 196 | 0.090 |
Why?
|
| Lamin Type A | 1 | 2011 | 2 | 0.090 |
Why?
|
| Research Design | 1 | 2012 | 157 | 0.090 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 72 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2002 | 72 | 0.080 |
Why?
|
| Adsorption | 1 | 2010 | 4 | 0.080 |
Why?
|
| Tissue Scaffolds | 1 | 2010 | 21 | 0.080 |
Why?
|
| Young Adult | 2 | 2012 | 1671 | 0.080 |
Why?
|
| Myocarditis | 1 | 2010 | 9 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2008 | 170 | 0.080 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2010 | 10 | 0.080 |
Why?
|
| Influenza Vaccines | 1 | 2010 | 9 | 0.080 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2010 | 12 | 0.080 |
Why?
|
| Nanoparticles | 1 | 2010 | 10 | 0.080 |
Why?
|
| Action Potentials | 2 | 2000 | 82 | 0.080 |
Why?
|
| Bungarotoxins | 1 | 2009 | 1 | 0.080 |
Why?
|
| Freund's Adjuvant | 1 | 2009 | 1 | 0.080 |
Why?
|
| Adolescent | 3 | 2018 | 1916 | 0.080 |
Why?
|
| Disease Progression | 2 | 2009 | 523 | 0.080 |
Why?
|
| Neuroimmunomodulation | 1 | 2009 | 7 | 0.080 |
Why?
|
| Protein Binding | 1 | 2009 | 115 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2006 | 153 | 0.070 |
Why?
|
| Alstrom Syndrome | 1 | 2008 | 1 | 0.070 |
Why?
|
| Caspase Inhibitors | 1 | 2008 | 5 | 0.070 |
Why?
|
| Fas-Associated Death Domain Protein | 1 | 2008 | 3 | 0.070 |
Why?
|
| Alternative Splicing | 1 | 2008 | 18 | 0.070 |
Why?
|
| Protein Isoforms | 1 | 2008 | 38 | 0.070 |
Why?
|
| Pilot Projects | 3 | 2005 | 378 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2009 | 281 | 0.070 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 76 | 0.070 |
Why?
|
| Enzyme Activation | 1 | 2008 | 110 | 0.070 |
Why?
|
| Cell Division | 1 | 2008 | 80 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2008 | 90 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2018 | 1425 | 0.070 |
Why?
|
| Sex Factors | 1 | 2009 | 389 | 0.070 |
Why?
|
| Radioimmunoassay | 2 | 2005 | 19 | 0.070 |
Why?
|
| Cell Line, Tumor | 1 | 2008 | 244 | 0.070 |
Why?
|
| Factor VII | 2 | 1997 | 2 | 0.070 |
Why?
|
| Factor X | 2 | 1997 | 2 | 0.070 |
Why?
|
| Age Factors | 1 | 2009 | 639 | 0.070 |
Why?
|
| Protein C | 2 | 1997 | 8 | 0.070 |
Why?
|
| Lipoprotein(a) | 2 | 1997 | 5 | 0.070 |
Why?
|
| Blood Coagulation | 2 | 1997 | 20 | 0.070 |
Why?
|
| Brachial Plexus Neuropathies | 1 | 2006 | 4 | 0.060 |
Why?
|
| Brachial Plexus | 1 | 2006 | 4 | 0.060 |
Why?
|
| Immunization | 1 | 2006 | 13 | 0.060 |
Why?
|
| Connective Tissue | 1 | 2006 | 19 | 0.060 |
Why?
|
| Time | 1 | 2006 | 14 | 0.060 |
Why?
|
| Spinal Nerve Roots | 1 | 2006 | 14 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 517 | 0.060 |
Why?
|
| Radiation Dosage | 1 | 2006 | 34 | 0.060 |
Why?
|
| Cell Communication | 1 | 2006 | 23 | 0.060 |
Why?
|
| Bronchopneumonia | 1 | 2006 | 1 | 0.060 |
Why?
|
| Opportunistic Infections | 1 | 2006 | 7 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2006 | 72 | 0.060 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2006 | 4 | 0.060 |
Why?
|
| Complement C1q | 1 | 2006 | 7 | 0.060 |
Why?
|
| Plasma Exchange | 2 | 2010 | 12 | 0.060 |
Why?
|
| Antigens | 1 | 2005 | 9 | 0.060 |
Why?
|
| Botulism | 1 | 2005 | 1 | 0.060 |
Why?
|
| Edrophonium | 1 | 2005 | 1 | 0.060 |
Why?
|
| Lambert-Eaton Myasthenic Syndrome | 1 | 2005 | 1 | 0.060 |
Why?
|
| Immunologic Tests | 1 | 2005 | 3 | 0.060 |
Why?
|
| Inflammation | 2 | 2004 | 229 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2021 | 578 | 0.060 |
Why?
|
| Biopsy | 3 | 2001 | 192 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2005 | 70 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 2005 | 72 | 0.060 |
Why?
|
| Carnitine | 1 | 2004 | 6 | 0.060 |
Why?
|
| Electric Stimulation | 1 | 2004 | 49 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2003 | 3026 | 0.050 |
Why?
|
| Muscle Contraction | 1 | 2004 | 67 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2003 | 105 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 166 | 0.050 |
Why?
|
| Motor Neuron Disease | 1 | 2002 | 4 | 0.050 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2002 | 3 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2002 | 60 | 0.050 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2001 | 11 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2003 | 592 | 0.040 |
Why?
|
| Uremia | 2 | 1998 | 4 | 0.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2000 | 15 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2021 | 83 | 0.040 |
Why?
|
| Prednisolone | 1 | 2000 | 8 | 0.040 |
Why?
|
| Tibial Nerve | 1 | 2000 | 4 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2000 | 12 | 0.040 |
Why?
|
| Facial Muscles | 1 | 1999 | 2 | 0.040 |
Why?
|
| Tongue | 1 | 1999 | 8 | 0.040 |
Why?
|
| Pedigree | 1 | 1999 | 51 | 0.040 |
Why?
|
| Hand Strength | 1 | 2000 | 49 | 0.040 |
Why?
|
| Muscular Dystrophies | 1 | 1999 | 2 | 0.040 |
Why?
|
| Hypertrophy | 1 | 1999 | 22 | 0.040 |
Why?
|
| Electrophysiology | 1 | 1999 | 95 | 0.040 |
Why?
|
| Biomarkers | 3 | 2012 | 476 | 0.040 |
Why?
|
| Hepatitis C, Chronic | 1 | 2000 | 42 | 0.040 |
Why?
|
| Arm | 1 | 1999 | 68 | 0.040 |
Why?
|
| Hemodiafiltration | 1 | 1998 | 2 | 0.040 |
Why?
|
| Biomimetics | 1 | 2018 | 6 | 0.040 |
Why?
|
| Epoprostenol | 1 | 1998 | 6 | 0.040 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 1998 | 4 | 0.040 |
Why?
|
| International Cooperation | 1 | 2018 | 14 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2000 | 218 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 1998 | 39 | 0.040 |
Why?
|
| Diet, Protein-Restricted | 1 | 1998 | 4 | 0.040 |
Why?
|
| Dietary Proteins | 1 | 1998 | 26 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 322 | 0.030 |
Why?
|
| Anticoagulants | 1 | 1998 | 84 | 0.030 |
Why?
|
| Vasculitis | 1 | 1997 | 26 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 1427 | 0.030 |
Why?
|
| United States | 2 | 2012 | 1820 | 0.030 |
Why?
|
| Injections, Subcutaneous | 2 | 2005 | 21 | 0.030 |
Why?
|
| Etanercept | 2 | 2005 | 21 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 875 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 236 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2006 | 439 | 0.020 |
Why?
|
| Advisory Committees | 1 | 2012 | 19 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 542 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2012 | 119 | 0.020 |
Why?
|
| Mutagenesis, Insertional | 1 | 2011 | 2 | 0.020 |
Why?
|
| Frameshift Mutation | 1 | 2011 | 4 | 0.020 |
Why?
|
| Codon, Nonsense | 1 | 2011 | 3 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2011 | 24 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2011 | 16 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2011 | 19 | 0.020 |
Why?
|
| Canada | 1 | 2011 | 45 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 149 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 187 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2011 | 79 | 0.020 |
Why?
|
| Hashimoto Disease | 1 | 2010 | 4 | 0.020 |
Why?
|
| Cell Line | 1 | 2011 | 250 | 0.020 |
Why?
|
| Encephalitis | 1 | 2010 | 10 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2010 | 51 | 0.020 |
Why?
|
| Steroids | 1 | 2010 | 22 | 0.020 |
Why?
|
| Phospholipids | 1 | 2010 | 9 | 0.020 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2010 | 18 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2010 | 44 | 0.020 |
Why?
|
| Brain Diseases | 1 | 2010 | 55 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2011 | 538 | 0.020 |
Why?
|
| Autopsy | 1 | 2010 | 257 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 338 | 0.020 |
Why?
|
| Complement C1 | 1 | 2006 | 1 | 0.020 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2006 | 2 | 0.020 |
Why?
|
| Complement C3 | 1 | 2006 | 4 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 2 | 1998 | 123 | 0.020 |
Why?
|
| Prognosis | 1 | 2005 | 740 | 0.010 |
Why?
|
| Time Factors | 1 | 2004 | 1275 | 0.010 |
Why?
|
| Leg | 1 | 2001 | 40 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2005 | 1512 | 0.010 |
Why?
|
| Fibrosis | 1 | 1999 | 30 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 1 | 1998 | 1 | 0.010 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 1998 | 2 | 0.010 |
Why?
|
| Prealbumin | 1 | 1998 | 4 | 0.010 |
Why?
|
| Creatinine | 1 | 1998 | 40 | 0.010 |
Why?
|
| Nutritional Status | 1 | 1998 | 52 | 0.010 |
Why?
|
| Blood Proteins | 1 | 1997 | 17 | 0.010 |
Why?
|